Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Carcinoma, Hepatocellular 2Squamous Cell Carcinoma of Head and Neck 1Pancreatic Neoplasms 1Hematologic Neoplasms 1Coronavirus Infections 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1COVID-19 1

Interventions

Hydroxychloroquine 4Standard of Care 2Sodium Chloride 2COH04S1 COVID-19 vaccine 2BNT162 Vaccine 2Azithromycin 2tocilizumab 1palbociclib 1ogalvibart 1monalizumab 1crexavibart 1cilgavimab and tixagevimab drug combination 1avdoralimab 1XAV-19 1Specimen Handling 1Radiotherapy 1Medical Marijuana 1Losartan 1Janus Kinase Inhibitors 1Ivermectin 1Interleukin-7 1HuMax-IL8 1Gelsolin 1CVnCoV COVID-19 vaccine 1COVID-19 Vaccines 12019-nCoV Vaccine mRNA-1273 111-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 11-palmityl-2-(4-carboxybutyl)-sn-glycero-3-phosphocholine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × COVID-19 × HuMax-IL8 × Clear all
NCT04347226 2025-05-22

Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19

Columbia University

Phase 2 Terminated
43 enrolled 14 charts
Other hematologic neoplasm

COVID-19, Coronavirus Infections, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡